Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Abstract: An infusion pump including a pump actuator; a fluid assembly operable with the pump actuator, the fluid assembly including an outlet line; a housing configured at its front side to receive the fluid assembly and at its backside to mount in either a first orientation or a second orientation to an external support, wherein the housing supports the pump actuator and the fluid assembly in each of the orientations, and wherein the outlet line extends from a surface of the housing; a controller operably connected to the housing; and a display operably connected to the controller and supported by the front side of the housing, the display configured to be rotatable responsive so that information displayed by the display is oriented right-side-up regardless of whether the surface from which the output extends is in the first orientation or the second orientation.

Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Abstract: A medical fluid heating system operable with different supply voltages including first and second heater elements: first and second power lines, first, second and third switches in electrical communication with the first and second power lines, the switches configured such that (i) in a first switch state the first and second heater elements are placed in series, solely via a closing of the first switch, for operation with a first supply voltage applied to the first and second power lines, and (ii) in a second switch state the first and second heater elements are placed in parallel, via the second and third switches, for operation with a second supply voltage applied to the first and second power lines, and a control element configured to automatically set the switches in the first or the second switch state based upon a signal sent to the control element indicative of the first or the second supply voltage.

Abstract: A blood cleansing system includes: a weight scale; a container support device for supporting a container of a blood treating fluid, wherein the container support device includes: an attachment member for coupling the container support device to the weight scale; a joint body attached to the attachment member and configured to rotate about an axis of the attachment member; a support body secured to the joint body; and at least one container support extending from the support body, wherein the container support is configured to stably support the fluid container.

Abstract: A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Abstract: Systems and methods for removing hydrogen peroxide from water purification systems are provided. In a general embodiment, the present disclosure provides a water purification system including a water treatment unit, an electrodeionization unit and a hydrogen peroxide decomposition catalyst in fluid connection with the electrodeionization unit. The water purification system can be fluidly connected to a renal treatment system.

Abstract: A flow control manifold includes a valve housing having first and second inlets and an outlet. The valve housing defines a cavity sized to slideably engage a valve having a first position and a second position. The flow control manifold may further include a first flow path defined within the valve and a second flow path defined within the valve such that the first flow path fluidly couples the first and second inlets to the outlet along the second flow path when the valve is in the first position.

Abstract: In one embodiment an automated peritoneal dialysis (“APD”) machine includes: at least one pump; a logic implementer storing a plurality of therapy prescriptions by which to operate the at least one pump, each therapy prescription pre-approved for a particular patient; and an input device operating with the logic implementer to allow the patient to select one of the therapy prescriptions for a particular therapy. In another embodiment, the input device operating with the logic implementer allows a doctor/clinician to select or approve one of the therapy prescriptions to be run on the APD machine. In a further embodiment, the logic implementer is programmed to select or suggest one of the therapy prescriptions to be run on the is APD machine.

Abstract: A port assembly includes a housing with an opening and a bore therethrough, a slit septum disposed in the bore to control access through the opening, a base joined to the housing and having a membrane attached thereto, a perforator having a first end abutting the slit septum and a second end aligned with the membrane, and a resilient member disposed between the perforator and the base. The port assembly may be used in a fluid container that includes a receptacle for retaining a fluid, and at least one conduit in communication with the receptacle. The at least one conduit may be defined, at least in part, by the port assembly.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps: immobilizing VWF pro-peptide on an ion exchange resin, incubating the immobilized VWF pro-peptide with furin to obtain immobilized mature VWF, and isolating mature VWF from the ion exchange resin by elution.

Abstract: A peritoneal dialysis system includes: an automated peritoneal dialysis (“APD”) machine configured to remove ultrafiltrate (“UF”) from a patient and record how much UF has been removed; and a logic implementer configured to (i) form a first moving average UF removed trend, (ii) determine a trending range around the first moving average UF removed trend, (iii) determine at least one of an upper and lower UF removed limit from the trending range, (iv) form a second moving average UF removed trend, and (v) alert if the second moving average UF removed trend moves outside of the at least one UF removed limit.

Abstract: A dialysis system includes a dialysis instrument; a disposable cassette, the cassette including a rigid portion defining at least one pumping chamber, a pouch fitted over the rigid portion, the pouch including at least one flexible sheet sealed so as to provide a sealed environment inside the pouch; and wherein the instrument is configured to press the at least one flexible sheet against the pumping chamber to seal the pumping chamber for operation.